Opyl Ltd. (AU:OPL) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Opyl Limited has announced its first revenue from the TrialGen platform with a new contract worth up to A$30,000 with Brain Vector, a leader in personalized mental healthcare. The TrialGen platform will provide Brain Vector with a suite of services including Competitor Analysis, Trial Design Optimisation, and Probability of Success Analysis Simulation for up to 6 trials. This marks a notable achievement for Opyl, showcasing their AI technology’s potential to revolutionize clinical trial success and improve patient outcomes in the mental health sector.
For further insights into AU:OPL stock, check out TipRanks’ Stock Analysis page.